Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)
The purpose of this study is to determine whether S-1 and bevacizumab are safe in the treatment of unresectable or recurrent colorectal cancer
Colorectal Cancer
DRUG: S-1, Bevacizumab
Progression free survival, every course for first three courses, then every other course
Safety, Response rate, Time to progression, Time to treatment failure, Overall survival, Treatment situation, any time
The purpose of this study is to determine whether S-1 and bevacizumab are safe in the treatment of unresectable or recurrent colorectal cancer